AdjuTec Pharma AS

Introducing Our Newest Board Member and Chairman of the Board

Oslo, Norway, 02 October 2023 – AdjuTec Pharma AS is a privately held company developing antibiotic resistance breakers. We are thrilled to introduce our newest Board Member and Chairman of the Board, Øyvind Kongstun Arnesen, to the AdjuTec Pharma family! With an impressive background in the medical and pharmaceutical fields, Øyvind brings a wealth of knowledge and experience to our team.

Øyvind is a medical doctor (MD) with over a decade of clinical experience. He has also made significant contributions to the pharmaceutical industry, having served as Medical Director at BMS Norway and as Medical Director and Head of Clinical Operations at Boehringer Ingelheim.

But that's not all! Øyvind's leadership extends beyond these roles. He held the position of CEO at Ultimovacs from 2012 to 2020, showcasing his expertise in both the medical and business fields.

Currently, Øyvind chairs the Board for Oslo Cancer Cluster showcasing his commitment to advancing healthcare initiatives. Moreover, he plays a pivotal role as an independent advisor to RADFORSK Investeringsstiftelse and other investors in the life science sector.

We are honored to have Øyvind on board and look forward to his valuable contributions to our mission of developing antibiotic resistance breakers 🎉👏

About antimicrobial resistance (AMR) –

AMR is a global health threat with an estimated 5mill associated deaths, including 1.27mill deaths attributable to bacterial AMR in 2019. WHO has declared that AMR is one of the top 10 global public health threats facing humanity. Misuse of antimicrobials is the main driver in the development of drug-resistant pathogens. AMR results in prolonged hospital stays at intensive care units with increased costs to the healthcare system. Without effective antimicrobials, the success of modern medicine in treating and preventing infections during major surgery and cancer chemotherapy, can be jeopardized.

About AdjuTec Pharma

AdjuTec Pharma is a company that is dedicated to developing and providing novel antibiotic resistance breakers to the global market. The company technology offers a unique mechanism of action that inactivates bacterial defence enzymes and restores bacterial sensitivity to antibiotics. The company’s lead product is APC148, a selective zinc chelator targeting bacterial metallo-ß-lactamase (MBL) enzymes. The technology was invented by Professor Pål Rongved and his group at the Department of Pharmacy, University of Oslo. The Company is located at St. Olavs gate 5, 0165 - downtown Oslo.

For more information, please visit

Please contact:

Follow us on LinkedIn and Twitter